NEW YORK – EnPlusOne Biosciences said last week that it has raised $10 million in financing to scale and drive additional technical advancements of its ezRNA synthesis platform.
Northpond Ventures and Breakout Ventures led the financing round. In connection with the financing, Julia Moore, managing partner at Breakout Ventures, will join Watertown, Massachusetts-based EnPlusOne's board of directors.
EnPlusOne's ezRNA platform is a template-free, aqueous-based enzymatic RNA synthesis technology providing new approaches to manufacturing RNA therapeutics.
"We highly value the confidence of our investors as our team works to optimize, scale, and advance our ezRNA platform," Dan Ahlstedt, cofounder, chief operating officer, and board director of EnPlusOne, said in a statement. "Our goal is ambitious: scaling our siRNA platform and accelerating recent technical progress in the synthesis of high-purity guide RNA for gene editing."
Ahlstedt added in an email that the company's primary focus is on therapeutics manufacturing but that it "recognize[s] the utility of researchers gaining access" to its platform, as well.
EnPlusOne is a spinout of the Wyss Institute for Biologically Inspired Engineering at Harvard University and recently inked a partnership with the institute to develop disease-agnostic immunotherapeutic RNAs.